Browse the corpus

REFERENCES Aberg JA, Kaplan JE, Libman H, et al, "Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America," Clin Infect Dis , 2009, 49(5):651-81. [PubMed 19640227 ] DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, "Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents," February 12, 2013. Available at file://www.aidsinfo.nih.gov DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection," November 5, 2012. Available at file://aidsinfo.nih.gov DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, "Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States," July 31, 2012. Available at file://aidsinfo.nih.gov Foster RH and Faulds D, "Abacavir," Drugs, 1998, 55(5):729-36. [PubMed 9585869 ] Hetherington S, Hughes AR, Mosteller M, et al, "Genetic Variations in HLA-B Region and Hypersensitivity Reactions to Abacavir," Lancet , 2002, 359(9312):1121-2. [PubMed 11943262 ] Hughes W, McDowell JA, Shenep J, et al, "Safety and Single-Dose Pharmacokinetics of Abacavir (1592U89) in Human Immunodeficiency Virus Type 1-Infected Children," Antimicrob Agents Chemother , 1999, 43(3):609-15. [PubMed 10049275 ] Kline MW, Blanchard S, Fletcher CV, et al, "A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection," Pediatrics , 1999, 103(4):e47. Available at file://www.pediatrics.org/cgi/content/full/103/4/e47 [PubMed 10103339 ] Lucas A, Nolan D, and Mallal S, "HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity," J Antimicrob Chemother , 2007, 59(4):591-3. [PubMed 17317695 ] Mallal S, Nolan D, Witt C, et al, "Association Between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir," Lancet , 2002, 359(9308):727-32. [PubMed 11888582 ]

Lucas A, Nolan D, and Mallal S, "HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity," J Antimicrob Chemother , 2007, 59(4):591-3. [PubMed 17317695 ] Mallal S, Nolan D, Witt C, et al, "Association Between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir," Lancet , 2002, 359(9308):727-32. [PubMed 11888582 ] Paediatric European Network for Treatment of AIDS (PENTA), "Comparison of Dual Nucleoside-Analogue Reverse-Transcriptase Inhibitor Regimens With and Without Nelfinavir in Children with HIV-1 Who Have Not Previously Been Treated: The PENTA 5 Randomised Trial," Lancet , 2002, 359(9308):733-40. [PubMed 11888583 ] Peyriére H, Nicolas J, Siffert M, et al, "Hypersensitivity Related to Abacavir in Two Members of a Family," Ann Pharmacother , 2001, 35(10):1291-2. Topic 13176 Version 41.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1104-122.72.76.133-AD134220F8-S244013.14]